US 12,134,642 B2
Antibodies binding to α7β1 integrin antibodies and compositions thereof
Patrick Andre, Short Hills, NJ (US); Chun Chen, Albany, CA (US); and Scott Turner, Oakland, CA (US)
Assigned to Pliant Therapeutics, Inc., South San Francisco, CA (US)
Filed by Pliant Therapeutics, Inc., South San Francisco, CA (US)
Filed on Nov. 13, 2020, as Appl. No. 17/098,199.
Claims priority of provisional application 63/029,070, filed on May 22, 2020.
Claims priority of provisional application 63/009,020, filed on Apr. 13, 2020.
Claims priority of provisional application 62/935,732, filed on Nov. 15, 2019.
Prior Publication US 2021/0147526 A1, May 20, 2021
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 25/28 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 45/06 (2013.01); A61P 25/28 (2018.01); A61K 2039/505 (2013.01)] 15 Claims
 
1. A monoclonal antibody or an antigen-binding fragment thereof that binds to α7β1 integrin, wherein the antibody or the antigen-binding fragment comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises three complementarity determining regions (HCDRs 1-3) and the VL region comprises three complementarity determining regions (LCDRs 1-3), and wherein the VH region comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 14, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 3 and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 68; and the VL region comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 71, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 6 and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 7.